Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term monoclonal-antibody. Found 36 abstracts

no pagination
Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong CY, Hittelman WN, Wen XX, Marks JW, Cheung LH, Boland K, Li C, Adams GP, Rosenblum MG. Single-Chain Antibody-Based Immunotoxins Targeting Her2/neu: Design Optimization and Impact of Affinity on Antitumor Efficacy and Off-Target Toxicity. Molecular Cancer Therapeutics. 2012 Jan;11(1):143-53.
Lerner MB, D'Souza J, Pazina T, Dailey J, Goldsmith BR, Robinson MK, Johnson AT. Hybrids of a Genetically Engineered Antibody and a Carbon Nanotube Transistor for Detection of Prostate Cancer Biomarkers. Acs Nano. 2012 Jun;6(6):5143-9.   PMCID: PMC3383883
Miller J, Doss M, McQuillen R, Shaller CC, Tolner B, Yu JQ, Chester K, Robinson MK. Impact of expression system on the function of the C6.5 diabody PET radiotracer. Tumor Biology. 2012 Jun;33(3):617-27.   PMCID: not NIH funded
Tchou J, Wang LC, Selven B, Zhang HT, Conejo-Garcia J, Borghaei H, Kalos M, Vondeheide RH, Albelda SM, June CH, Zhang PJ. Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Research and Treatment. 2012 Jun;133(2):799-804.
Vadakara J, Pro B. Targeting CD30 in Anaplastic Large Cell Lymphoma. Current Hematologic Malignancy Reports. 2012 Dec;7(4):285-91.   PMCID: Not NIH fund
Zhou Y, Goenaga AL, Harms BD, Zou H, Lou JL, Conrad F, Adams GP, Schoeberl B, Nielsen UB, Marks JD. Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies. Molecular Cancer Therapeutics. 2012 Jul;11(7):1467-76.
Robertson FM, Ogasawara MA, Ye ZM, Chu K, Pickei R, Debeb BG, Woodward WA, Hittelman WN, Cristofanilli M, Barsky SH. Imaging and Analysis of 3D Tumor Spheroids Enriched for a Cancer Stem Cell Phenotype. Journal of Biomolecular Screening. 2010 Aug;15(7):820-9.   PMCID: not NIH funded
Robinson MK, Alpaugh RK, Borghaei H. Naptumomab estafenatox: a new immunoconjugate. Expert Opinion on Biological Therapy. 2010 Feb;10(2):273-9.   PMCID: not NIH funded
Schaer DA, Cohen AD, Wolchok JD. Anti-GITR antibodies - Potential clinical applications for tumor immunotherapy. Current Opinion in Investigational Drugs. 2010 Dec;11(12):1378-86.   PMCID: not NIH funded
Borghaei H, Alpaugh K, Hedlund G, Forsberg G, Langer C, Rogatko A, Hawkins R, Dueland S, Lassen U, Cohen RB. Phase I Dose Escalation, Pharmacokinetic and Pharmacodynamic Study of Naptumomab Estafenatox Alone in Patients With Advanced Cancer and With Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology. 2009 Sep;27(25):4116-23.   PMCID: PMC2734423
de Camargo VP, van de Rijn M, de Alava E, Madoz-Gurpide J, Pilotti S, von Mehren M, Pedeutour F, Maki RG, Rutkowski P, Thomas DM. Other Targetable Sarcomas. Seminars in Oncology. 2009 Aug;36(4):358-71.   PMCID: not NIH funded
Stein R, Smith MR, Chen S, Zalath M, Goldenberg DM. Combining Milatuzumab with Bortezomib, Doxorubicin, or Dexamethasone Improves Responses in Multiple Myeloma Cell Lines. Clinical Cancer Research. 2009 Apr;15(8):2808-17.   PMCID: PMC 2681251
O'Regan RM, Osipo C, Ariazi E, Lee ES, Meeke K, Morris C, Bertucci A, Sarker MA, Grigg R, Jordan VC. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice. CLINICAL CANCER RESEARCH. 2006 Jan;12(7):2255-63.
Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M, Rocha K, Wang HG, Richon V, Bhalla K. Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of Her-2. Clinical Cancer Research. 2005 Sep;11(17):6382-9.
Kucher C, Zhang PJ, Pasha T, Elenitsas R, Wu H, Ming ME, Elder DE, Xu XW. Expression of Melan-A and Ki-67 in desmoplastic melanoma and desmoplastic Nevi. American Journal of Dermatopathology. 2004 Dec;26(6):452-7.
Cohen SJ, Meropol NJ. Drug development in pancreatic cancer - Finally, biology begets therapy. International Journal of Gastrointestinal Cancer. 2002 Jan;32(2-3):91-106.
Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-Lopez AJ, White CA. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood. 2002 Jun 15;99(12):4336-42.
Nielsen UB, Adams GP, Weiner LM, Marks JD. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Research. 2000 Nov 15;60(22):6434-40.
McCall AM, Adams GP, Amoroso AR, Nielsen UB, Zhang L, Horak E, Simmons H, Schier R, Marks JD, Weiner LM. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis. Molecular immunology. 1999 May;36(7):433-45.
Sauter ER, Nesbit M, Watson JC, Klein-Szanto A, Litwin S, Herlyn M. Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clinical Cancer Research. 1999 Apr;5(4):775-82.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term monoclonal-antibody

monoclonal-antibody in-vitro growth-factor receptor antigen phase-ii carcinoma tumors single-chain fv tumor spheroids protein superantigen fusion proteins antitumor-activity library tumor-therapy receptor metastatic breast-cancer pancreatic cancer tyrosine kinase inhibitor first-line therapy metastatic melanoma malignant-melanoma trial Breast cancer subtypes Mesothelin-Triple negative breast cancer-Chimeric antigen receptor-Immunotherapy vaccines i clinical-trials gastric epithelial-cells proliferation advanced colorectal-cancer carbon nanotube biosensor-field effect transistor-cancer diagnostics Her-2 metastatic colorectal-cancer mAbs neu-overexpressing metastatic breast differential 1989 audhary vk-nature-v339-p394 non-hodgkins-lymphoma phase-i trial modeling analysis in-vivo botulinum neurotoxin bispecific s100 protein recognition binding-properties tissue-sections renal cell carcinoma melan-a thermo-reversible cell SEA her2 animal toxicity CD30 Anaplastic large cell lymphoma-SGN-35-Brentuximab-Vedotin-MMAE-T-cell lymphoma ribosome-inactivating proteins colony-stimulating factor inflammatory breast-carcinoma enzyme fusion combination term follow-up tyrosinase affinity receptors filamentous 2002 llo sp-biol chem-v383-p69 soft part apoptosis cd74 randomized-trial biodistribution k1 phage cancer gene dose-escalation fragment ii cycloaddition VEGF transcription factor foxp3 Foxp3 Cancer-GITR-immunotherapy-regulatory T-cell staphylococcal enterotoxin-a brentuximab vedotin sgn-35 apoptosis-inducing ligand ovarian-cancer pichia-pastoris induced tnf receptor free click chemistry human angiogenin subtypes matrix metalloproteinase inhibitors myelodysplastic syndrome Oncology down-regulation dexamethasone fc-gamma-riii estrogen-receptor breast-carcinoma neu phage display library cd16 plasma osteopontin gastrointestinal stromal tumors combination immunotherapy site barrier hla-dr phase-i scFv NSCLC cytokines identification costimulatory receptor Ki-67 positron-emission-tomography lines superantigen HER2 Diabody-Pichia-E coli-PET imaging serum-cholesterol giant-cell tumor immunotoxin rfb4(dsfv)-pe38 desmoplastic 2-chlorodeoxyadenosine biosensors benign imaging carcinomas leukemia-cells anti-cd30 recombinant immunotoxin inflammatory breast cancer sarcoma confocal microscopy FTI mouse gitr chemotherapy tissue 1992 ang k-american journal of surgical pathology-v16-p259 lymphovascular binding angiogenesis therapy neu solid postmenopausal women factor-i receptor peptides t-lymphocytes histone deacetylase inhibitor sensitivity overdose control survival factor-related early prediction
Last updated on Tuesday, April 02, 2019